minktherapeutics.com (INKT): Rasio rega marang prakiraan pendapatan

INKT (MiNK Therapeutics Inc.) - tandha merek perusahaan

MiNK Therapeutics, Inc. (INKT) maintains high authority within the oncology community, attracting specialized funds. Manufacturing capacities in Massachusetts are supplemented by US-based CDMO plants, while current revenue is based on investments prior to the market launch of its solid tumor therapy. The forward price-to-sales ratio demonstrates capital dynamics, where the 237.60 mark indicates the level of market expectations regarding the company's future sales.

INKT MiNK Therapeutics Inc.: Rasio kapitalisasi pasar marang pendapatan mangsa ngarep ing interval 14.11.2026 - 18.11.2026

Rincian analitis perusahaan MiNK Therapeutics, Inc. (INKT)

- data kapitalisasi bursa:
Ringkesan analisis perusahaan:minktherapeutics.com INKT
Produk sing diprodhuksi MiNK Therapeutics, Inc

The forward P/S ratio assesses the market value of a business relative to projected sales volume, allowing for the determination of the premium paid for future cash flows. By analyzing the expected price-to-sales ratio, an investor can mitigate the risk of purchasing an overheated asset, which is critical for MiNK Therapeutics, Inc. (INKT), whose capitalization relies on the uniqueness of cell therapy and strict FDA oversight within clinical trials.

Analisis pesaing

ImmunityBio Inc - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S Immunocore Corp IMCR|JANX - Rasio rega marang prakiraan pendapatan|RCUS (arcusbio.com) - Kapitalisasi marang prakiraan pendapatan|Zymeworks Biopharmaceuticals (ZYME) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Tango Pharma (TNGX)|Multiplikator forward rega marang pendapatan IOVA|IMTX - Prakiraan rega marang pendapatan|Multiplikator forward rega marang pendapatan XNCR (Xencor Corp)|Rasio rega marang pendapatan sing dikarepake CMPX|Multiplikator Forward P/S REPL (Replimune)|Rega forward marang dodolan LYEL|innate-pharma.com - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Pyxis Oncology|Compugen Limited (CGEN) - Rasio rega marang prakiraan pendapatan|IO Biotech, Inc. - Rega forward marang dodolan|STRO (sutrobio.com) - Multiplikator Forward P/S|Multiplikator Forward P/S werewolftx.com|Rasio rega marang prakiraan pendapatan immixbio.com (IMMX)|ALXO: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S CUE (Cue Biopharma Inc.)|PDS Biotechnology (PDSB) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|SONN - Rasio rega marang prakiraan pendapatan|MAIA Biotechnology, Inc. (MAIA) - Multiplikator forward rega marang pendapatan|LIMN: Multiplikator Forward P/S|LAVA Therapeutics N.V. (LVTX) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan NXTC|Multiplikator Forward P/S leaptx.com|Multiplikator Forward P/S INTS|Rasio kapitalisasi marang dodolan sing dikarepake Sensei Biotherapeutics, Inc.|Multiplikator Forward P/S TOVX (Theriva Corp)|Rasio kapitalisasi marang dodolan sing dikarepake gritstonebio.com (GRTS)|kinetabio.com - Multiplikator Forward P/S|NexImmune (NEXI) - Multiplikator forward rega marang pendapatan|turnstonebio.com (TSBX) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Vaccinex, Inc (VCNX)|Multiplikator forward rega marang pendapatan HARP